10x Genomics (NASDAQ:TXG) Price Target Raised to $14.00

10x Genomics (NASDAQ:TXG) had its target price upped by UBS Group from $13.00 to $14.00 in a research note released on Friday,Benzinga reports. UBS Group currently has a neutral rating on the stock.

TXG has been the subject of several other reports. Canaccord Genuity Group set a $16.00 price objective on 10x Genomics in a research note on Monday, August 11th. Deutsche Bank Aktiengesellschaft set a $14.00 price objective on shares of 10x Genomics and gave the stock a “hold” rating in a research note on Friday, August 8th. Piper Sandler began coverage on 10x Genomics in a report on Thursday, September 11th. They set a “neutral” rating and a $15.00 target price on the stock. Barclays raised their price target on 10x Genomics from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Wall Street Zen raised 10x Genomics from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, 10x Genomics currently has a consensus rating of “Hold” and an average price target of $14.58.

10x Genomics Price Performance

Shares of 10x Genomics stock opened at $15.25 on Friday. 10x Genomics has a 12 month low of $6.78 and a 12 month high of $17.25. The firm’s fifty day simple moving average is $12.81 and its 200-day simple moving average is $11.79. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -24.60 and a beta of 2.13.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.05. The business had revenue of $149.00 million during the quarter, compared to analysts’ expectations of $142.50 million. 10x Genomics had a negative return on equity of 11.71% and a negative net margin of 11.89%.The company’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.30) earnings per share. 10x Genomics has set its Q4 2025 guidance at EPS. Analysts anticipate that 10x Genomics will post -1.43 earnings per share for the current year.

Insider Activity at 10x Genomics

In other 10x Genomics news, CFO Adam Taich sold 22,315 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $307,723.85. Following the completion of the sale, the chief financial officer owned 309,273 shares in the company, valued at $4,264,874.67. This trade represents a 6.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Serge Saxonov sold 9,348 shares of the business’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $128,908.92. Following the completion of the sale, the chief executive officer directly owned 945,892 shares of the company’s stock, valued at $13,043,850.68. The trade was a 0.98% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 39,149 shares of company stock valued at $539,865. Insiders own 10.03% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Syon Capital LLC boosted its position in 10x Genomics by 183.4% during the 3rd quarter. Syon Capital LLC now owns 41,772 shares of the company’s stock worth $488,000 after acquiring an additional 27,035 shares during the period. Axxcess Wealth Management LLC lifted its position in shares of 10x Genomics by 10.1% in the third quarter. Axxcess Wealth Management LLC now owns 15,045 shares of the company’s stock worth $176,000 after purchasing an additional 1,376 shares in the last quarter. Fortis Group Advisors LLC acquired a new stake in shares of 10x Genomics during the third quarter worth approximately $236,000. GSA Capital Partners LLP grew its position in 10x Genomics by 708.9% during the third quarter. GSA Capital Partners LLP now owns 121,144 shares of the company’s stock valued at $1,416,000 after purchasing an additional 106,167 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in 10x Genomics by 6.7% in the 3rd quarter. Vanguard Group Inc. now owns 13,274,332 shares of the company’s stock valued at $155,177,000 after buying an additional 834,272 shares during the period. Hedge funds and other institutional investors own 84.68% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.